ENA Respiratory.png
Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
February 13, 2023 08:00 ET | ENA Respiratory
-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. -- These results support the further...
ENA Respiratory.png
Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections
January 30, 2023 08:00 ET | ENA Respiratory
-- ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations---- Survey was conducted...
ENA Respiratory.png
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
January 09, 2023 08:00 ET | ENA Respiratory
-- Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats MELBOURNE, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Clinical-stage pharmaceutical company...
ENA Respiratory.png
ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
May 11, 2022 08:00 ET | ENA Respiratory
SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for...
ENA Respiratory.png
First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray
March 15, 2022 08:00 ET | ENA Respiratory
ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections ...
ENA Respiratory.png
ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
February 23, 2022 08:00 ET | ENA Respiratory
-- INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of...
ENA Respiratory.png
First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials
September 28, 2021 08:00 ET | ENA Respiratory
-- ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost...
ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose
July 13, 2021 08:00 ET | ENA Respiratory
-- First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal...
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round
June 15, 2021 08:00 ET | ENA Respiratory
Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051Company appoints President and Chief Scientific Officer of...